Stock listing

Aquis:ACES Ascelia Pharma AB Share Price

UK listing (Aquis) of Ascelia Pharma AB · home listing Stockholm:ACE

Follow Ascelia Pharma AB into a list and get an email when it puts out news.

Home listing price · OMXSTO:ACE

0.58 SEK 0.00 (0.0%)

Close on Oct 30, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:ACE

Past year -81.6% · daily closes, Oct 30, 2025 – Oct 30, 2026, adjusted for splits
Day range
0.55 – 0.588 SEKOct 30, 2026
Volume
157,034 sharesOct 30, 2026
Market cap
77.45M SEKAt the close on Oct 30, 2026 · price × 133.5M shares outstanding
52-week range
0.455 – 3.55 SEKLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
Traded on an average day
664,620 SEKMedian day 683,348 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Ascelia Pharma AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:ACE · Home0.58 SEK0.00 (0.0%)157,0340.580.5880.550.58Close on Oct 30, 2026
Frankfurt:7ZA€0.045 EUR+0.006 (+14.0%)—€0.045€0.045€0.045€0.039Close on Oct 30, 2026

Daily closes

Last 3 months, Jul 30, 2026 – Oct 30, 2026 · OMXSTO:ACE · SEK, adjusted for splits

DayCloseChange%OpenHighLowVolume
0.580.000.0%0.580.5880.55157,034
0.58+0.065+12.6%0.5220.5880.514768,378
0.515-0.005-1.0%0.5180.5320.512261,963
0.52-0.008-1.5%0.5410.5410.517422,042
0.528+0.008+1.5%0.520.550.511243,966
0.52+0.01+2.0%0.520.540.51176,030
0.51+0.004+0.8%0.5120.570.51600,903
0.506-0.012-2.3%0.5190.5790.504480,174
0.518-0.017-3.2%0.5350.5350.507460,192
0.535-0.027-4.8%0.5620.6350.5351,086,850
0.562+0.024+4.5%0.5390.580.539495,089
0.538-0.042-7.2%0.5710.5710.511,414,855
0.58-0.095-14.1%0.6490.6490.581,285,125
0.675-0.005-0.7%0.680.6930.6011,085,173
0.68-0.18-20.9%0.650.7030.514,584,675
0.86+0.004+0.5%0.8380.8980.801,569,400
0.856+0.156+22.3%0.7010.890.7011,914,185
0.70-0.102-12.7%0.8020.8020.70756,786
0.802-0.018-2.2%0.8440.8440.782870,590
0.82+0.01+1.2%0.8410.9340.803,460,165
0.81+0.011+1.4%0.7990.8550.7991,238,986
0.799+0.007+0.9%0.7870.9140.7722,627,116
0.792+0.161+25.5%0.6351.0580.6316,108,157
0.631-0.016-2.5%0.6460.6530.62745,979
0.647+0.004+0.6%0.6430.6620.63471,060
0.643+0.014+2.2%0.6290.6440.602455,596
0.629+0.009+1.5%0.6010.6450.601331,322
0.620.000.0%0.620.6270.585457,906
0.62+0.012+2.0%0.6080.6390.597203,713
0.608-0.018-2.9%0.6270.650.60638,607
0.626+0.053+9.2%0.5930.6490.573372,777
0.573-0.029-4.8%0.6150.6150.571329,679
0.602-0.02-3.2%0.600.6320.60313,194
0.622+0.003+0.5%0.6170.6290.59441,588
0.619-0.018-2.8%0.6440.6510.612315,917
0.637-0.005-0.8%0.640.670.624558,050
0.642-0.016-2.4%0.6590.6590.631478,183
0.658+0.013+2.0%0.6450.6590.638377,243
0.645+0.003+0.5%0.630.6480.62785,205
0.6420.000.0%0.6420.6420.642739,283
0.642+0.012+1.9%0.6370.6460.621250,012
0.63+0.023+3.8%0.6070.6370.60828,846
0.607-0.008-1.3%0.6150.6150.5821,068,956
0.615-0.016-2.5%0.630.6340.591897,025
0.6310.000.0%0.6140.6310.611351,955
0.631+0.008+1.3%0.6030.6320.603683,348
0.623-0.003-0.5%0.6310.6390.6031,527,374
0.626+0.018+3.0%0.6240.6380.61677,149
0.608-0.007-1.1%0.6150.640.6062,043,032
0.615+0.005+0.8%0.610.650.5982,270,121
0.61+0.02+3.4%0.570.6170.5611,142,953
0.59+0.04+7.3%0.5980.5980.553748,708
0.55-0.027-4.7%0.5750.5880.5451,043,988
0.577-0.023-3.8%0.6010.6010.542,231,590
0.60+0.025+4.3%0.5510.660.5513,065,489
0.575-0.005-0.9%0.580.5840.55818,650
0.58-0.004-0.7%0.560.5830.55413,249
0.584+0.004+0.7%0.580.5840.55477,352
0.58+0.01+1.8%0.5610.5830.552327,860
0.57-0.029-4.8%0.5990.600.557881,564
0.599+0.009+1.5%0.590.5990.555572,581
0.59+0.011+1.9%0.6040.6040.554670,558
0.579-0.026-4.3%0.6050.6290.562824,011
0.605+0.07+13.1%0.5350.6690.5212,004,271
0.535+0.002+0.4%0.5330.5370.51770,113
0.533+0.023+4.5%0.5230.540.509539,053
0.51-0.012-2.3%0.5250.5260.502337,789
Ticker
Aquis:ACES
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Aquis
Currency
SEK

What changed lately

Calls

Replays

  • Ascelia Pharma (Stockholm:ACE) Q2 2026 Earnings Call

    Thu, Aug 20, 2026 · 4:00 AM ET

    Watch Transcript

  • Ascelia Pharma (Stockholm:ACE) Q1 2026 Earnings Call

    Tue, May 12, 2026 · 4:00 AM ET

    Watch Transcript

  • Ascelia Pharma (Stockholm:ACE) Q4 2025 Earnings Call

    Thu, Feb 05, 2026 · 4:00 AM ET

    Watch Transcript

Latest news

Ascelia Pharma Announces Publication of Orviglance Clinical Study in Journal of Magnetic Resonance Imaging

Sep 24, 2026

Closed 0.629 (+1.5%) on Sep 24, 2026

Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA

Sep 10, 2026

Closed 0.642 (-2.4%) on Sep 10, 2026

Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on September 9, 2026

Aug 17, 2026

Closed 0.60 (+4.3%) on Aug 17, 2026

Ascelia Pharma Announces Organizational Changes and a Reduced Cost Base

Jul 15, 2026

Closed 0.509 (+7.2%) on Jul 15, 2026

Ascelia Pharma Provides Update on the Orviglance NDA

Jul 3, 2026

Closed 0.808 (-75.4%) on Jul 3, 2026

Ascelia Pharma Expands Orviglance IP Portfolio with New Patent Filing

Jun 30, 2026

Closed 2.96 (+1.0%) on Jun 30, 2026

Ascelia Pharma Carries Out a Directed Share Issue of SEK 20 Million

Apr 23, 2026

Closed 3.15 (-2.3%) on Apr 24, 2026

Notice of Annual General Meeting in Ascelia Pharma AB

Mar 30, 2026

Closed 2.89 (+5.9%) on Mar 31, 2026

Ascelia Pharma Announces Acceptance of Orviglance Data for Oral Presentation at the Annual Radiology Congress ESGAR 2026

Mar 27, 2026

Closed 2.89 (-2.5%) on Mar 27, 2026

Ascelia Pharma Announces Deputy CEO Julie Waras Brogren to Leave the Company

Jan 21, 2026

Closed 2.83 (-10.9%) on Jan 21, 2026

All Ascelia Pharma AB news

Decks

Ascelia Pharma AB on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 19 in all · newest Sep 24, 2026 · oldest 2025
Calls
10 calls with a replay · 10 with a transcript · latest Aug 20, 2026
Decks
8 decks · latest Aug 20, 2026

Where Ascelia Pharma AB is listed

ListingExchangeCountryCurrency
Stockholm:ACE · Home listingStockholmSwedenSEK
Aquis:ACESAquisUnited KingdomSEK
Aquis:ACES · This pageAquisUnited KingdomSEK
Frankfurt:7ZAFrankfurtGermanyEUR

Log in to ask 6ix AI your own questions about Ascelia Pharma AB.